JP2023533961A - 線維性疾患およびがんを処置するための化合物、組成物、および方法 - Google Patents

線維性疾患およびがんを処置するための化合物、組成物、および方法 Download PDF

Info

Publication number
JP2023533961A
JP2023533961A JP2023500997A JP2023500997A JP2023533961A JP 2023533961 A JP2023533961 A JP 2023533961A JP 2023500997 A JP2023500997 A JP 2023500997A JP 2023500997 A JP2023500997 A JP 2023500997A JP 2023533961 A JP2023533961 A JP 2023533961A
Authority
JP
Japan
Prior art keywords
compound
alkyl
optionally substituted
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533961A5 (https=
Inventor
エス． ロウ，フィリップ
ヴィクター ナポレオン，ジョン
チャン，フェンファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2023533961A publication Critical patent/JP2023533961A/ja
Publication of JP2023533961A5 publication Critical patent/JP2023533961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023500997A 2020-07-08 2021-07-07 線維性疾患およびがんを処置するための化合物、組成物、および方法 Pending JP2023533961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049556P 2020-07-08 2020-07-08
US63/049,556 2020-07-08
PCT/US2021/040736 WO2022011043A2 (en) 2020-07-08 2021-07-07 Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer

Publications (2)

Publication Number Publication Date
JP2023533961A true JP2023533961A (ja) 2023-08-07
JP2023533961A5 JP2023533961A5 (https=) 2025-02-20

Family

ID=79553738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500997A Pending JP2023533961A (ja) 2020-07-08 2021-07-07 線維性疾患およびがんを処置するための化合物、組成物、および方法

Country Status (7)

Country Link
US (1) US20230248835A1 (https=)
EP (1) EP4178574A4 (https=)
JP (1) JP2023533961A (https=)
CN (1) CN115916342A (https=)
AU (1) AU2021305193A1 (https=)
CA (1) CA3184740A1 (https=)
WO (1) WO2022011043A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996715A4 (en) * 2019-07-08 2024-01-03 Purdue Research Foundation COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER
EP4271378A4 (en) * 2021-01-04 2026-03-11 Purdue Research Foundation METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT
EP4683669A2 (en) * 2023-03-23 2026-01-28 Purdue Research Foundation Combinations and methods for enhancing checkpoint inhibitor therapies in cancer treatment
CN119215159A (zh) * 2024-09-24 2024-12-31 深圳市格茵莱生物科技有限公司 树突状细胞多抗原负载免疫治疗方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512370A (ja) * 2003-11-25 2007-05-17 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
JP2007517044A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
JP2007530579A (ja) * 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
JP2010526129A (ja) * 2007-05-08 2010-07-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
JP2018525426A (ja) * 2015-08-31 2018-09-06 スリーエム イノベイティブ プロパティズ カンパニー グアニジン置換イミダゾ［４，５−ｃ］環状化合物
WO2019048353A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES AS TLR7 AGONISTS
JP2019519524A (ja) * 2016-05-25 2019-07-11 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法
WO2020139618A1 (en) * 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413558A (pt) * 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
DE212016000029U1 (de) * 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
WO2020023680A1 (en) * 2018-07-24 2020-01-30 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
AU2019335366A1 (en) * 2018-09-07 2021-03-25 Birdie Biopharmaceuticals, Inc. Imidazoquinoline compounds and uses thereof
WO2020236253A1 (en) * 2019-05-20 2020-11-26 Massachusetts Institute Of Technology Boronic ester prodrugs and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512370A (ja) * 2003-11-25 2007-05-17 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
JP2007517044A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
JP2007530579A (ja) * 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
JP2010526129A (ja) * 2007-05-08 2010-07-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
JP2018525426A (ja) * 2015-08-31 2018-09-06 スリーエム イノベイティブ プロパティズ カンパニー グアニジン置換イミダゾ［４，５−ｃ］環状化合物
JP2019519524A (ja) * 2016-05-25 2019-07-11 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法
WO2019048353A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES AS TLR7 AGONISTS
WO2020139618A1 (en) * 2018-12-26 2020-07-02 Birdie Biopharmaceuticals, Inc. Immune modulatory combinations and methods for treating cancers

Also Published As

Publication number Publication date
WO2022011043A3 (en) 2022-03-03
WO2022011043A2 (en) 2022-01-13
EP4178574A2 (en) 2023-05-17
EP4178574A4 (en) 2024-04-10
AU2021305193A1 (en) 2023-02-09
CA3184740A1 (en) 2022-01-13
CN115916342A (zh) 2023-04-04
US20230248835A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN115192577B (zh) Kras突变蛋白抑制剂
JP2023533961A (ja) 線維性疾患およびがんを処置するための化合物、組成物、および方法
AU2007257423B2 (en) Purine analogs
US9908880B2 (en) Substituted imidazoquinolines
EP2809660B1 (en) Macrocyclic compounds for modulating il-17
ES3060380T3 (en) Immunomodulator
CN113195469B (zh) 含氮并环化合物、其制备方法及用途
JP2013032290A (ja) 新規縮合ピリミジン誘導体
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CN112824399B (zh) 一种免疫调节剂
CN114585621B (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用
US20250195524A1 (en) Pyrimido-pyridazinone compound as toll-like receptor agonist
CN114599360A (zh) 4-氨基-咪唑并喹啉化合物及其用途
US11453688B2 (en) Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
CN119371430A (zh) 喜树碱类小分子及其抗体药物偶联物、制备方法和应用
US20230303562A1 (en) Pyrazole compound and preparation method therefor and use thereof
WO2024112932A1 (en) Immunomodulators and immunomodulator conjugates
CN121627680A (zh) 一种吡唑并吡啶类化合物、组合物及其用途
CN120053678A (zh) 一种高喜树碱类抗体偶联药物、其制备方法及应用
TW202434597A (zh) 抑制15-pgdh的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303